의약품 위탁생산 시장(2026-2030년)

The global pharmaceutical contract manufacturing market is forecasted to grow by USD 76396.2 mn during 2025-2030, accelerating at a CAGR of 8.2% during the forecast period. The report on the global pharmaceutical contract manufacturing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing complexity and cost of research and development, growing need to focus on core competencies, surging demand for advanced therapeutic modalities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global pharmaceutical contract manufacturing market is segmented as below:

By End-User

• Big pharmaceutical companies
• Small and medium-sized pharmaceutical companies
• Generic pharmaceutical companies

By Service

• API and bulk drug manufacturing
• Final dosage form
• Secondary packaging

By Application

• Infectious diseases
• Cardiovascular diseases
• Oncology

Geography

• North America
  • US
  • Canada
  • Mexico
• Asia
• Europe
  • Germany
  • UK
  • France
  • The Netherlands
  • Italy
  • Spain
  • Switzerland
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the strategic onshoring and supply chain resilience in north america and europe as one of the prime reasons driving the global pharmaceutical contract manufacturing market growth during the next few years. Also, rising demand for biological therapies and intensifying cost-containment pressures and pursuit of operational efficiency will lead to sizable demand in the market.

The report on the global pharmaceutical contract manufacturing market covers the following areas:

• Global pharmaceutical contract manufacturing market sizing
• Global pharmaceutical contract manufacturing market forecast
• Global pharmaceutical contract manufacturing market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global pharmaceutical contract manufacturing market vendors that include AbbVie Inc., Aenova Holding GmbH, Ajinomoto Co. Inc., Almac Group Ltd., Boehringer Ingelheim GmbH, Cadila Pharmaceuticals Ltd., Cambrex Corp., Catalent Inc., Charles River Laboratories, Cmic Holdings Co. Ltd., Corden Pharma Intl. GmbH, Dr. Reddys Laboratories Ltd., Evonik Industries AG, Lonza Group Ltd., PCI Pharma Services, Recipharm AB, Samsung Biologics Co. Ltd., Siegfried Holding AG, Thermo Fisher Scientific Inc., WuXi Biologics Cayman Inc.. Also, the global pharmaceutical contract manufacturing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Service
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Pharmaceutical Contract Manufacturing Market 2020 - 2024
  • Historic Market Size - Data Table on Global Pharmaceutical Contract Manufacturing Market 2020 - 2024 ($ million)
• 5.2 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.3 Service segment analysis 2020 - 2024
  • Historic Market Size - Service Segment 2020 - 2024 ($ million)
• 5.4 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in Global Pharmaceutical Contract Manufacturing Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by End-user

• 8.1 Market segments
• 8.2 Comparison by End-user
• 8.3 Big pharmaceutical companies - Market size and forecast 2025-2030
• 8.4 Small and medium-sized pharmaceutical companies - Market size and forecast 2025-2030
• 8.5 Generic pharmaceutical companies - Market size and forecast 2025-2030
• 8.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

9 Market Segmentation by Service

• 9.1 Market segments
• 9.2 Comparison by Service
• 9.3 API and bulk drug manufacturing - Market size and forecast 2025-2030
• 9.4 Final dosage form - Market size and forecast 2025-2030
• 9.5 Secondary packaging - Market size and forecast 2025-2030
• 9.6 Market opportunity by Service
  • Market opportunity by Service ($ million)

10 Market Segmentation by Application

• 10.1 Market segments
• 10.2 Comparison by Application
• 10.3 Infectious diseases - Market size and forecast 2025-2030
• 10.4 Cardiovascular diseases - Market size and forecast 2025-2030
• 10.5 Oncology - Market size and forecast 2025-2030
• 10.6 Market opportunity by Application
  • Market opportunity by Application ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Asia - Market size and forecast 2025-2030
  • 12.4.1 China - Market size and forecast 2025-2030
  • 12.4.2 India - Market size and forecast 2025-2030
  • 12.4.3 Japan - Market size and forecast 2025-2030
  • 12.4.4 South Korea - Market size and forecast 2025-2030
  • 12.4.5 Singapore - Market size and forecast 2025-2030
  • 12.4.6 Indonesia - Market size and forecast 2025-2030
  • 12.4.7 Thailand - Market size and forecast 2025-2030
• 12.5 Europe - Market size and forecast 2025-2030
  • 12.5.1 Germany - Market size and forecast 2025-2030
  • 12.5.2 UK - Market size and forecast 2025-2030
  • 12.5.3 France - Market size and forecast 2025-2030
  • 12.5.4 The Netherlands - Market size and forecast 2025-2030
  • 12.5.5 Italy - Market size and forecast 2025-2030
  • 12.5.6 Spain - Market size and forecast 2025-2030
  • 12.5.7 Switzerland - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Australia - Market size and forecast 2025-2030
  • 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 South Africa - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing complexity and cost of research and development
  • Growing need to focus on core competencies
  • Surging demand for advanced therapeutic modalities
• 13.2 Market challenges
  • Heightened regulatory scrutiny and complexity
  • Stereotypical nature of contract manufacturing organizations
  • Stringent regulations on contract manufacturing organizations
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Strategic onshoring and supply chain resilience in North America and Europe
  • Rising demand for biological therapies
  • Intensifying cost-containment pressures and pursuit of operational efficiency

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 15.5 Aenova Holding GmbH
  • Aenova Holding GmbH - Overview
  • Aenova Holding GmbH - Product / Service
  • Aenova Holding GmbH - Key offerings
  • SWOT
• 15.6 Ajinomoto Co. Inc.
  • Ajinomoto Co. Inc. - Overview
  • Ajinomoto Co. Inc. - Business segments
  • Ajinomoto Co. Inc. - Key news
  • Ajinomoto Co. Inc. - Key offerings
  • Ajinomoto Co. Inc. - Segment focus
  • SWOT
• 15.7 Almac Group Ltd.
  • Almac Group Ltd. - Overview
  • Almac Group Ltd. - Product / Service
  • Almac Group Ltd. - Key offerings
  • SWOT
• 15.8 Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH - Overview
  • Boehringer Ingelheim GmbH - Product / Service
  • Boehringer Ingelheim GmbH - Key news
  • Boehringer Ingelheim GmbH - Key offerings
  • SWOT
• 15.9 Cadila Pharmaceuticals Ltd.
  • Cadila Pharmaceuticals Ltd. - Overview
  • Cadila Pharmaceuticals Ltd. - Product / Service
  • Cadila Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.10 Cambrex Corp.
  • Cambrex Corp. - Overview
  • Cambrex Corp. - Product / Service
  • Cambrex Corp. - Key offerings
  • SWOT
• 15.11 Catalent Inc.
  • Catalent Inc. - Overview
  • Catalent Inc. - Business segments
  • Catalent Inc. - Key offerings
  • Catalent Inc. - Segment focus
  • SWOT
• 15.12 Charles River Laboratories
  • Charles River Laboratories - Overview
  • Charles River Laboratories - Business segments
  • Charles River Laboratories - Key offerings
  • Charles River Laboratories - Segment focus
  • SWOT
• 15.13 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.14 Evonik Industries AG
  • Evonik Industries AG - Overview
  • Evonik Industries AG - Business segments
  • Evonik Industries AG - Key news
  • Evonik Industries AG - Key offerings
  • Evonik Industries AG - Segment focus
  • SWOT
• 15.15 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key news
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.16 PCI Pharma Services
  • PCI Pharma Services - Overview
  • PCI Pharma Services - Product / Service
  • PCI Pharma Services - Key offerings
  • SWOT
• 15.17 Recipharm AB
  • Recipharm AB - Overview
  • Recipharm AB - Business segments
  • Recipharm AB - Key offerings
  • Recipharm AB - Segment focus
  • SWOT
• 15.18 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations